Letter--The Authors Respond

J Manag Care Spec Pharm. 2017 May;23(5):599-600. doi: 10.18553/jmcp.2017.23.5.599.

Abstract

None of the authors of this study are involved in financial or personal relationships with agencies, institutions, or organizations that inappropriately influenced the statistical analysis plan or interpretation of the study results. DiDomenico received an honorarium from Amgen for the preparation of a heart failure drug monograph for Pharmacy Practice News and was a coinvestigator on funded research for the Patient-Centered Outcomes Research Institute. DiDomenico also serves as an advisory board member for a heart failure program at Otsuka America Pharmaceuticals and as an advisory board member at Novartis Pharmaceuticals. Touchette has received unrestricted grant funding from Cardinal Health and Sunovion Pharmaceuticals and has also served as a consultant to, and director of, the American College of Clinical Pharmacy Practice-Based Research Network on a study funded by Pfizer.

Publication types

  • Comment

MeSH terms

  • Acute Coronary Syndrome*
  • Humans
  • Patient Outcome Assessment
  • Percutaneous Coronary Intervention*
  • Pharmaceutical Services*
  • Purinergic P2Y Receptor Antagonists
  • United States

Substances

  • Purinergic P2Y Receptor Antagonists